The statistics are grim. For patients fighting an aggressive form of leukemia known as acute myeloid leukemia, or AML, doctors over the last 40 years have usually used a combination of two drugs to fight the disease, but it seldom cures it.    

About two thirds of the patients initially respond to the drugs, but most relapse and the disease comes back. Only 25 percent of the patients with AML survive long term, noted ISCRM's Pamela Becker.

“About 10 years ago, we realized that everyone’s leukemia is different from one another,” Becker said. Patient cases, however, are treated with much the same approach, in terms of first-line drug therapies.

In a paper published this week in Nature Communications, Becker and colleagues focused on key genes to fight this disease, and to do so, they needed to sort through the 17,000 genes present in each leukemia cell.

Read more here.